Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
Search
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
expanded-collaboration-MD-Anderson
The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
View from Both Sides of the Table
Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
Fish Pie
This comforting fish pie from Taking Cancer on Through Flavour is full of protein to keep you feeling satisfied for longer[node:body][node:title]
New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Real stories, real impact: fighting rabies
The danger of rabies is often overlooked. The need for action, unseen. Learn how we can eliminate rabies through leveraging education and dog vaccinations.
PREVEXXION® RN: Marek’s disease vaccine available in EU UK
Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
FRONTLINE® becomes Brand of the Year 2021-22
FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Heart Diseases in humans and animals
Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well.
Boehringer and ZEISS partnership eye diseases
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
FRONTLINE becomes Brand of the Year 2019-2020
FRONTLINE becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards
Alexandra Breiner
Alexandra Breiner: ways to learn and grow
Acquisition Saint-Herblon site and Coophavet brand
Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site
Liu
Hear Liu share his experience of being diagnosed with type 2 diabetes and heart disease on the same day and the impact this simultaneous diagnosis has had on his life as he knew it.
Elke
People with Type 2 diabetes (T2D) have an increased risk of heart disease.
Isabel
In this video, Isabel shares how watching her children and grandchildren grow up inspires her to take the necessary steps to manage her life with type 2 diabetes and heart disease.
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones